FDA Approved New Once-Weekly Insulin for Type 2 Diabetes
Adults with type 2 diabetes now have a new long-acting insulin option to help manage blood sugar levels alongside lifestyle habits.
Updated on Sept. 24, 2026 in Diabetes
Live Poll
Do you view the approval of new weekly insulin treatments as an improvement for patient care?
The FDA approved Onswik on September 24, 2026, for the treatment of adults with type 2 diabetes. The medication is a long-acting insulin analog designed to be injected once weekly as an adjunct to diet and exercise.
Why it matters
This approval introduces a once-weekly basal insulin option for patients managing type 2 diabetes. By reducing the frequency of injections, this medication may offer a new approach to maintaining long-term glycemic control for eligible adults.
The FDA granted approval for Onswik based on its function as a once-weekly basal insulin analog for adults with type 2 diabetes. This regulatory decision confirms the drug's role in improving glycemic control when used in conjunction with diet and exercise.
The players
FDA
The federal agency responsible for regulating pharmaceuticals and public health safety in the United States.
Eli Lilly and Company
A global pharmaceutical manufacturer focused on developing treatments for metabolic disorders, including diabetes.
The details
Onswik functions as a long-acting basal insulin analog that is administered via injection once per week. By providing a consistent release of insulin into the bloodstream over a seven-day period, the drug helps patients improve their glycemic control. It is specifically formulated to be used as an adjunct to a consistent diet and exercise regimen.
Timeline
September 24, 2026: The FDA officially approved the medication Onswik.
Health Landscape
This drug marks a significant advancement in the development of long-acting basal insulin analogs, shifting the standard of care from daily to weekly dosing. The approval reflects a broader trend in endocrinology aimed at simplifying complex medication regimens for chronic metabolic disease.
If you are currently managing type 2 diabetes with daily insulin, discuss with your doctor whether a once-weekly injectable option might be appropriate for your specific care plan. This conversation should include an assessment of your current glycemic targets and any lifestyle factors affecting your insulin needs.
The takeaway
The move toward once-weekly basal insulin represents a shift in how patients may manage their blood sugar levels. Talk to your healthcare provider to track your glucose patterns and determine if new, less frequent treatment options are a fit for your long-term health goals.
Further reading
Learn more about evolving treatment options by visiting our Diabetes section.
Source note: This article includes information reported by Drugs.
Live Poll
Do you view the approval of new weekly insulin treatments as an improvement for patient care?
